Top Markets
Coin of the day
Chinook Therapeutics, Inc. Chinook Therapeutics, Inc.

Chinook Therapeutics, Inc.

KDNY
Rangering i aksjer #7143
Chinook Therapeutics, Inc., a biotechnology enterprise in the clinical... Chinook Therapeutics, Inc., a biotechnology enterprise in the clinical development phase, is dedicated to the identification, progression, and market introduction of precise medical treatments for kidney-related conditions. The company's primary therapeutic candidate, atrasentan, is an endothelin receptor antagonist currently in Phase III clinical trials. This drug aims to treat IgA nephropathy and various other glomerular diseases characterized by proteinuria. Beyond its lead program, Chinook's investigational pipeline includes BION-1301, an anti-APRIL monoclonal antibody, which is presently being evaluated in a Phase I/II study for IgA nephropathy. Another promising candidate is CHK-336, an oral small molecule designed to inhibit LDHA, intended for patients with primary hyperoxaluria. The firm also maintains active research initiatives exploring solutions for other uncommon and severe chronic kidney ailments. Chinook Therapeutics, Inc. is based in Seattle, Washington.
Aksjekurs
$40.39
Sist synkronisert: 2023-08-18
Markedsverdi
$1.70B
Endring (1 dag)
0.00%
Endring (1 år)
0.00%
Land
US
Handel Chinook Therapeutics, Inc. (KDNY)

Kategori

Aksjeprishistorikk for Chinook Therapeutics, Inc. (KDNY)
Høyeste sluttskurs: $40.34 den 2023-08-01

Laveste sluttskurs: $177.63 den 2015-04-01
Aksjeprishistorikk for Chinook Therapeutics, Inc. fra 2015 til 2026
Årlig aksjeprisytelse
År Ytelse
2023 63.66%
2022 55.54%
2021 0.37%
2020 175.05%
2019 -57.15%
2018 -67.16%
2017 -26.51%
2016 -62.61%
2015 0.00%
Aksjepris for lignende selskaper eller konkurrenter
Selskap Aksjepris Endring 1år% Land
$548.36 39.87%
US
$1.06K 50.29%
NL
$121.53 -12.48%
AU
$140.81 475.44%
US
$765.25 7.74%
CH